Cancer pathology reports contain information which is critical for patient management and for cancer surveillance, resource planning, and quality purposes. The College of American Pathologists (CAP) has defined scientifically validated content of checklists that form the basis for synoptic cancer pathology reporting. We outline how the CAP standards were implemented in a large Canadian province over a 3-year period resulting in improvements in rates of synoptic reporting and completeness of cancer pathology reporting.J. Surg. Oncol. 2009;99:517-524. ß 2009 Wiley-Liss, Inc. KEY WORDS: cancer pathology; standardization; synoptics; population study; outcomes INTRODUCTIONThe great majority of cancers are diagnosed through the combined efforts of surgeons and pathologists. A clear and thorough recording of the surgical and pathological findings allows assessment of diagnosis and prognosis, and thus facilitates treatment decisions for patients. In recent years, the complexity of cancer pathology reporting has significantly increased. The adequate surgical pathology report not only documents the presence and accurate typing of cancer but also contains information related to tumor grade, size, local extent, vessel involvement, marginal status along with other morphologic and sometimes ancillary results including tumor markers. In some tumor types, for instance breast cancer, the list of carcinoma descriptors can be quite daunting [1].There are four essential elements of quality in cancer pathology reporting: timeliness, accuracy, completeness, and usability. The timeliness or turnaround time of a cancer pathology report is clearly important as is the accuracy of the diagnostic and prognostic observations. The completeness of a cancer pathology report relative to an accepted standard is also an important reflection of overall quality. Cancer pathology reports should be timely, correct, and contain all the relevant information required for diagnosis, prognosis, and further treatment decisions. A fourth dimension of quality is the usability or accessibility of the data in the report.There is a spectrum of cancer pathology reporting which is shown in Table I. The range includes simple narrative reporting using a single text field of data without mandatory scientifically validated data elements as defined by the College of American Pathologists (CAP) (level 1 reporting) to sophisticated synoptic reporting with drop down menus, standardized language, discrete data fields, and automated ICD-O and/or SNOMED CT encoding (level 6). In practice most cancer pathology reports lie somewhere in the middle.Cancer pathology reports given in a synoptic format are intuitively easier to decipher than ones that are presented in a narrative or paragraphic style, minimizing the risk of misinterpretation and clinical error. Synoptic reporting can save time since all important diagnostic and prognostic factors are laid out in a list or table with headers and responses rather than being buried in paragraphic text fields. While cancer patholog...
Introduction: The objective is to provide guidance on the role of active surveillance (AS) as a management strategy for low-risk prostate cancer patients and to ensure that AS is offered to appropriate patients assessed by a standardized protocol. Prostate cancer is often a slowly progressive or sometimes non-progressive indolent disease diagnosed at an early stage with localized tumours that are unlikely to cause morbidity or death. Standard active treatments for prostate cancer include radiotherapy (RT) or radical prostatectomy (RP), but the harms from over diagnosis and overtreatment are of a significant concern. AS is increasingly being considered as a management strategy to avoid or delay the potential harms caused by unnecessary radical treatment. Methods: A literature search of MEDLINE, EMBASE, the Cochrane library, guideline databases and relevant meeting proceedings was performed and a systematic review of identified evidence was synthesized to make recommendations relating to the role of AS in the management of localized prostate cancer. Results: No exiting guidelines or reviews were suitable for use in the synthesis of evidence for the recommendations, but 59 reports of primary studies were identified. Due to studies being either non-comparative or heterogeneous, pooled meta-analyses were not conducted. Conclusion:The working group concluded that for patients with low-risk (Gleason score ≤6) localized prostate cancer, AS is the preferred disease management strategy. Active treatment (RP or RT) is appropriate for patients with intermediate-risk (Gleason score 7) localized prostate cancer. For select patients with low-volume Gleason 3+4=7 localized prostate cancer, AS can be considered.
Radiation treatment for cancer requires patients to receive frequent administrations and attend the treatment facility on a daily basis for several weeks. Travelling for radiation treatment has the potential to add to the distress an individual may be feeling. This study utilized in-depth interviews to capture 118 patients' perspectives about travelling for cancer treatment. Four themes emerged during the analysis of the data: (1) waiting was the most difficult part of the experience; (2) the idea of travelling for treatment was distressing; (3) travelling for treatment was tiring and posed difficulties for patients; and (4) being away from home had both benefits and drawbacks. Given the inevitability of travelling for radiation treatment, and the issues that arises for patients, supportive strategies need to be designed and implemented.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.